← Leaderboards
Shu G Chen
Case Western Reserve University
$11,007,717
Attributed
$22,180,036
Total exposure
9
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.3M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,180,036 · 9
By mechanism
R01$16,829,061 · 4
U01$3,661,408 · 1
R21$1,205,522 · 3
P01$484,045 · 1
Top collaborators
- Allison L Kraus12 shared
- Zerui Wang8 shared
- Bin Xu5 shared
- Rong Xu5 shared
- Steven A. Gunzler4 shared
- Qingzhong Kong3 shared
- John J Mieyal2 shared
- Amy L Wilson-Delfosse2 shared
Most similar at Case Western Reserve University
Same institution · by research overlap
- Pierluigi Gambetti$33,097,698
- Allison L Kraus$5,232,285
- Ignazio Cali$740,106
- Amy L Wilson-Delfosse$144,631
- John J Mieyal$4,307,881
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposBrainS DiseaseNeurodegenerative DisordersTau ProteinsAffectDetectionAutopsyAlpha SynucleinDiagnosisSkinTauopathiesDementiaBiological MarkersSeverity Of IllnessBiopsy SpecimenDepositionDiagnostic TestsSamplingCadaverCorticobasal DegenerationProgressive Supranuclear PalsyProtein AggregationSpecimen
Grant awards (38)
Peripheral Tissue Biomarker for Premortem Diagnosis of Lewy Body Dementia$1,090,231
R01 · FY2025 · NS · contact PI
Skin biomarkers for diagnosing and characterizing AD and ADRD$727,876
R01 · FY2025 · AG
Peripheral Biomarkers for Early Diagnosis of Mixed Pathologies in AD/ADRD$719,976
R01 · FY2025 · AG · contact PI
Skin biomarkers for diagnosing and characterizing AD and ADRD$751,076
R01 · FY2024 · AG
Peripheral Biomarkers for Early Diagnosis of Mixed Pathologies in AD/ADRD$743,879
R01 · FY2024 · AG · contact PI
Peripheral Tissue Biomarker for Premortem Diagnosis of Lewy Body Dementia$1
R01 · FY2024 · NS · contact PI
Peripheral Tissue Biomarker for Premortem Diagnosis of Lewy Body Dementia$1,090,232
R01 · FY2023 · NS · contact PI
Skin biomarkers for diagnosing and characterizing AD and ADRD$757,758
R01 · FY2023 · AG
Peripheral Biomarkers for Early Diagnosis of Mixed Pathologies in AD/ADRD$756,004
R01 · FY2023 · AG · contact PI
Assessing skin biomarkers for preclinical diagnosis of PD and non-PD Parkinsonism$729,340
U01 · FY2023 · NS
Peripheral Tissue Biomarker for Premortem Diagnosis of Lewy Body Dementia$1,989,864
R01 · FY2022 · NS · contact PI
Skin biomarkers for diagnosing and characterizing AD and ADRD$755,388
R01 · FY2022 · AG
Assessing skin biomarkers for preclinical diagnosis of PD and non-PD Parkinsonism$709,041
U01 · FY2022 · NS
Combine computational prediction, network analysis and genetic screening in C elegans to uncover neurodegenerative causes in Alzheimer's Disease$708,999
R01 · FY2022 · AG
Peripheral Tissue Biomarker for Premortem Diagnosis of Lewy Body Dementia$1,090,232
R01 · FY2021 · NS · contact PI
Peripheral Tissue Biomarker for Premorten Diagnosis of Lewy Body Dementia$975,214
R01 · FY2021 · NS · contact PI
Skin biomarkers for diagnosing and characterizing AD and ADRD$842,164
R01 · FY2021 · AG
Assessing skin biomarkers for preclinical diagnosis of PD and non-PD Parkinsonism$709,041
U01 · FY2021 · NS
Combine computational prediction, network analysis and genetic screening in C elegans to uncover neurodegenerative causes in Alzheimer's Disease$708,999
R01 · FY2021 · AG
Peripheral Tissue Biomarker for Premortem Diagnosis of Lewy Body Dementia$1,133,032
R01 · FY2020 · NS · contact PI
Assessing skin biomarkers for preclinical diagnosis of PD and non-PD Parkinsonism$743,089
U01 · FY2020 · NS
Combine computational prediction, network analysis and genetic screening in C elegans to uncover neurodegenerative causes in Alzheimer's Disease$729,794
R01 · FY2020 · AG
Assessing skin biomarkers for preclinical diagnosis of PD and non-PD Parkinsonism$770,897
U01 · FY2019 · NS
Combine computational prediction, network analysis and genetic screening in C elegans to uncover neurodegenerative causes in Alzheimer's Disease$623,171
R01 · FY2019 · AG
Combine computational prediction, network analysis and genetic screening in C elegans to uncover neurodegenerative causes in Alzheimer's Disease$635,171
R01 · FY2018 · AG
Glutaredoxin, a Critical Regulator of Parkinson Disease Pathogenesis$196,143
R21 · FY2014 · NS · contact PI
Glutaredoxin, a Critical Regulator of Parkinson Disease Pathogenesis$237,750
R21 · FY2013 · NS · contact PI
Assay Development and Discovery of LRRK2 Inhibitors for Parkinson Disease$192,325
R21 · FY2011 · NS · contact PI
Assay Development and Discovery of LRRK2 Inhibitors for Parkinson Disease$235,500
R21 · FY2010 · NS · contact PI
Structure-Activity Analysis of LRRK2 Associated:PD$153,769
R21 · FY2007 · AG · contact PI
Structure-Activity Analysis of LRRK2 Associated:PD$190,035
R21 · FY2006 · AG · contact PI
MOLECULAR STUDIES OF HUMAN AND ANIMAL PRION PROTEINS$0
P01 · FY2002 · AG
IN VITRO MODEL OF PHENOTYPIC DIVERSITY IN PRION DISEASES$0
P01 · FY2002 · AG
IN VITRO MODEL OF PHENOTYPIC DIVERSITY IN PRION DISEASES$254,615
P01 · FY2001 · AG
IN VITRO MODEL OF PHENOTYPIC DIVERSITY IN PRION DISEASES$0
P01 · FY2001 · AG
IN VITRO MODEL OF PHENOTYPIC DIVERSITY IN PRION DISEASES$0
P01 · FY2001 · AG
IN VITRO MODEL OF PHENOTYPIC DIVERSITY IN PRION DISEASES$0
P01 · FY2001 · AG
IN VITRO MODEL OF PHENOTYPIC DIVERSITY IN PRION DISEASES$229,430
P01 · FY2000 · AG